Shipping
Same-day shipping on USA orders placed before 2PM EST.
View Shipping Policy →
99%+ Purity Guaranteed
Research Use Only
Secure Checkout
GHRP-2 5mg
SKU: GHRP25M
Same Trusted Formula. Fresh New Look.During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly the same as per our standards.
Accepted Payment MethodsYour data is protected with 256-bit encryption.
Returns
30-day hassle-free returns on unopened products.
View Returns Policy →Lab Tested
Every batch is tested for purity, potency and quality.
View Lab Results →Support
Have a question? Our team is here to help you.
Contact Us →GHRP-2 (Pralmorelin) is a synthetic hexapeptide compound studied for selective ghrelin receptor binding properties and growth hormone secretagogue signalling in experimental models. The compound consists of six amino acids (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2) and is examined for its capacity to engage the GHS-R1a (growth hormone secretagogue receptor 1a) in pituitary and hypothalamic research models. Research applications include ghrelin receptor pharmacology, growth hormone secretagogue pathway studies, and pulsatile GH signalling research.
- High Purity — 99%+ Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure of C45H55N9O6
CarbonHydrogenFluorineNitrogenOxygenSulfur
| Chemical Formula | C45H55N9O6 |
|---|---|
| Synonyms | Pralmorelin, KP-102, D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide, UNII-E6S6E1F19M |
| Molar Mass | 817.9865 g/mol |
| CAS Number | 158861-67-7 |
| PubChem CID | 6918245 |
| Total Compound Content | 5mg per vial |
| Shelf Life | 36 months |
GHRP-2 (Pralmorelin) is a synthetic hexapeptide studied as a potent agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in laboratory research models. The compound's six-amino-acid sequence (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2) is studied for selective receptor binding at GHS-R1a sites located in pituitary somatotroph cells and hypothalamic nuclei, with downstream research interest in pulsatile growth hormone secretagogue signalling and IGF-1 axis modulation. Research models have also examined GHRP-2's proposed somatostatin suppression activity — studied as a mechanism through which it may amplify growth hormone release beyond direct receptor agonism — and its capacity to modulate cAMP production, calcium mobilization, and PKA/PKC signalling cascades in pituitary cell models. Independently third-party HPLC-tested; COA available per batch.
No lab reports have been added yet.
What receptor does GHRP-2 bind to and how is this studied in laboratory models?
GHRP-2 is studied for selective agonist activity at the GHS-R1a (growth hormone secretagogue receptor 1a), which is expressed in pituitary somatotroph cells and hypothalamic nuclei. Cell-based binding assays using GHS-R1a-expressing cell lines, alongside downstream signalling readouts (such as cAMP accumulation and calcium mobilization), are standard methods for characterising GHRP-2's receptor engagement and functional potency relative to other GHS-R1a ligands.
What distinguishes GHRP-2's proposed mechanism from GHRH-based research tools?
GHRP-2 engages the ghrelin/GHS-R1a receptor pathway, distinct from the GHRH receptor pathway targeted by GHRH analogues such as CJC-1295. Research protocols frequently pair GHRP-2 with GHRH analogues to examine whether GHS-R1a agonism and GHRH receptor activation produce synergistic effects on growth hormone secretagogue signalling endpoints, a common combination design in pituitary pathway research.
What experimental controls are commonly used in GHRP-2 receptor-signalling research?
Studies investigating GHRP-2 mechanisms typically incorporate vehicle controls, receptor-antagonist controls, and comparator GHS-R1a agonists to distinguish receptor-specific effects from non-specific pathway activation. Comparative experiments using compounds such as GHRP-6 or Ipamorelin are commonly employed to evaluate differences in signalling selectivity, pathway activation patterns, receptor responsiveness, and downstream transcriptional responses. These approaches help establish mechanistic attribution in GHS-R1a pharmacology research.
-
-
-
- Sale
